Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient

• Published in: Scandinavian journal of infectious diseases Vol. 44; no. 8; pp. 626 - 629
• Main Authors: Tsuji, Yasuhiro, Hiraki, Yoichi, Matsumoto, Kana, Mizoguchi, Akiko, Sadoh, Shinichi, Kobayashi, Tsutomu, Sakamoto, Seisaburo, Morita, Kunihiko, Yukawa, Eiji, Kamimura, Hidetoshi, Karube, Yoshiharu
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01.08.2012
• Subjects: Acetamides - administration & dosage; Acetamides - blood; Acetamides - pharmacokinetics; Adult; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - blood; Anti-Bacterial Agents - pharmacokinetics; Humans; Japan; Linezolid; Lung Diseases - drug therapy; Lung Diseases - metabolism; Male; Methicillin-Resistant Staphylococcus aureus - isolation & purification; Obesity - metabolism; Oxazolidinones - administration & dosage; Oxazolidinones - blood; Oxazolidinones - pharmacokinetics; Staphylococcal Infections - drug therapy; Staphylococcal Infections - metabolism; Japan
• ISSN: 0036-5548; 1651-1980
• DOI: 10.3109/00365548.2011.652164

Abstract We evaluated the pharmacokinetics of linezolid in the case of an obese Japanese patient (body weight 116 kg; body mass index 37 kg/m2). Linezolid was administered at a dose of 600 mg by intravenous drip infusion for 60-90 min at 12-h intervals. The results showed increased clearance of linezolid and a reduced serum concentration compared to population pharmacokinetic parameters, with trough levels below the 90% minimum inhibitory concentration. However, linezolid was effective for improving lung infection and inflammation in our patient, which may be due to its particularly effective transfer into lung tissues. Linezolid undergoes slow non-enzymatic oxidation in vivo that may be increased in obese patients, and this may account for the greater clearance. Our findings are useful for the planning of linezolid therapy in obese patients.